Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Shi‐qing Chen"'
Autor:
Wu-tong Ju, Rong-hui Xia, Dong-wang Zhu, Sheng-jin Dou, Guo-pei Zhu, Min-jun Dong, Li-zhen Wang, Qi Sun, Tong-chao Zhao, Zhi-hang Zhou, Si-yuan Liang, Ying-ying Huang, Yong Tang, Si-cheng Wu, Jing Xia, Shi-qing Chen, Yue-zong Bai, Jiang Li, Qi Zhu, Lai-ping Zhong
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
In patients with locally advanced resectable oral squamous cell carcinoma (OSCC), the risk of recurrence and metastasis following treatment is high. Here, a phase I clinical trial reports safety and pathological response of neoadjuvant camrelizumab a
Externí odkaz:
https://doaj.org/article/860026b443204a60b588c854d620d01d
Autor:
Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian, Min-Juan Hu, Ding Zhang, Shi-Qing Chen, Jun Lu, Shu-Hui Cao, Jing-Wen Li, Yue Wang, Bo Zhang, Shu-Yuan Wang, Chang-Hui Li, Ping Yang, Mi–Die Xu, Xue-Yan Zhang, Hua Zhong, Bao-Hui Han
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work b
Externí odkaz:
https://doaj.org/article/43312b339c054c13bd77d56ebf24ec7f
Autor:
Ling Peng, Qi-Qi Mao, Bo Jiang, Jin Zhang, Yi-Lei Zhao, Xiao-Dong Teng, Jin-Song Yang, Yang Xia, Shi-Qing Chen, Justin Stebbing, Hai Jiang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Immune checkpoint inhibitors (ICIs) cause fewer toxicities than conventional chemotherapy. Although most of the immune-related adverse events (irAEs) are mild, reversible, and manageable, potentially severe and rare irAEs remain relevant. We present
Externí odkaz:
https://doaj.org/article/1d3d6e17982949a2a9d96a8816c17f39
Autor:
Shi-qing Chen, Bing-feng Hu, Ya-ru Yang, Yuan He, Lin Yue, Dong Guo, Ting-ni Wu, Xiao-wen Feng, Qing Li, Wei Zhang, Jia-gen Wen
Publikováno v:
Biochemical and Biophysical Research Communications. 612:91-98
Nephrotoxicity is a major adverse reaction of cisplatin-based chemotherapy. Organic cation transporter 2 (OCT2) which is located on the basement membrane of human proximal renal tubules is responsible for the renal accumulation of cisplatin and its n
Autor:
Xiang-Yu Wang, Rui Zhang, Jia-Hao Han, Shi-Qing Chen, Fei-Long Zhao, Hui Chen, Jing Lin, Jie Fan, Wen-Wei Zhu, Lu Lu, Jin-Hong Chen
Publikováno v:
Annals of Surgical Oncology.
Autor:
Xiang-Yu Wang, Rui Zhang, Jia-Hao Han, Shi-Qing Chen, Fei-Long Zhao, Hui Chen, Jing Lin, Jie Fan, Wen-Wei Zhu, Lu Lu, Jin-Hong Chen
Publikováno v:
Annals of Surgical Oncology.
Autor:
Shun Lu, Yiping Zhang, Zhijian Sun, Chan Gao, Ting Bei, Chunwei Xu, Wenxian Wang, Feng Hua, Xiaoyu Wu, Shenpeng Ying, Yuping Li, Jianjin Huang, Shi-Qing Chen, Dongqing Lv, Zhengbo Song
Purpose:In this study, we aimed to evaluate the efficacy and safety of pyrotinib, a pan-HER inhibitor, in patients with HER2-amplified non–small cell lung cancer (NSCLC).Patients and Methods:In this prospective, multicenter, single-arm trial (ChiCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ee770f57e1a5364d1d263e5f716591
https://doi.org/10.1158/1078-0432.c.6532401
https://doi.org/10.1158/1078-0432.c.6532401
Autor:
Shun Lu, Yiping Zhang, Zhijian Sun, Chan Gao, Ting Bei, Chunwei Xu, Wenxian Wang, Feng Hua, Xiaoyu Wu, Shenpeng Ying, Yuping Li, Jianjin Huang, Shi-Qing Chen, Dongqing Lv, Zhengbo Song
Supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f41b2a9215480d4f2ece173898f36b8
https://doi.org/10.1158/1078-0432.22486836.v1
https://doi.org/10.1158/1078-0432.22486836.v1
Autor:
Shun Lu, Yiping Zhang, Zhijian Sun, Chan Gao, Ting Bei, Chunwei Xu, Wenxian Wang, Feng Hua, Xiaoyu Wu, Shenpeng Ying, Yuping Li, Jianjin Huang, Shi-Qing Chen, Dongqing Lv, Zhengbo Song
Supplementary tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aebeb9dc55aa457b965bb05d04b6313
https://doi.org/10.1158/1078-0432.22486833.v1
https://doi.org/10.1158/1078-0432.22486833.v1
Publikováno v:
World Journal of Clinical Cases
BACKGROUND The FGFR signaling pathway is activated in multiple tumor types through gene amplifications, single base substitutions, or gene fusions. Novel FGFR gene fusions may represent candidate targets for the development of tyrosine kinase inhibit